Document Detail


Alteration of the glycosylation pattern of monocytic THP-1 cells upon differentiation and its impact on lectin-mediated drug delivery.
MedLine Citation:
PMID:  19602437     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the present study, human monocytic THP-1 cells were treated with phorbol-12-myristate-13-acetate (PMA) in order to obtain macrophage-like cells. Before and after treatment, plant lectins with distinct sugar specificities were applied in order to elucidate the glycosylation patterns of both monocytic and macrophage-like cell types and to follow changes during differentiation. As a result of flow-cytometric analyses, for untreated as well as for PMA-differentiated cells WGA yielded the highest binding rate without significant changes in the binding capacity. For the other lectins, divergent results were obtained which point to reorganization of sugar residues on the cell surface during differentiation. Additionally, cytoinvasion being beneficial for enhanced drug absorption was studied with WGA which had displayed a high binding capacity together with a high specificity. For both untreated and PMA-differentiated cells decreased fluorescence intensity at 37 degrees C as compared to 4 degrees C was observable pointing to internalization and accumulation within acidic compartments. Moreover, WGA-functionalized PLGA nanoparticles were prepared, and their uptake evaluated. Uptake rates of 55% in case of PMA-differentiated cells suggested that WGA-grafted drug delivery systems might be an interesting approach for treatment of infectious diseases provoked by parasites, facultative intracellular bacteria, or viruses such as HIV.
Authors:
V E Plattner; G Ratzinger; E T Engleder; S Gallauner; F Gabor; M Wirth
Related Documents :
9207247 - Intranuclear translocation of phospholipase c beta2 during hl-60 myeloid differentiation.
2209717 - Analysis of nuclear sugar-binding components in undifferentiated and in vitro different...
20807017 - Elastic properties of induced pluripotent stem cells.
20487827 - Transition between isozymic forms of enolase during in vitro differentiation of neurobl...
19460967 - Spontaneous [ca2+]i oscillations in g1/s phase-synchronized cells.
8373417 - Antisense and sense cdna expression cloning using autonomously replicating vectors and ...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2009-07-12
Journal Detail:
Title:  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft f??r Pharmazeutische Verfahrenstechnik e.V     Volume:  73     ISSN:  1873-3441     ISO Abbreviation:  Eur J Pharm Biopharm     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-05     Completed Date:  2010-01-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109778     Medline TA:  Eur J Pharm Biopharm     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  324-30     Citation Subset:  IM    
Affiliation:
Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbohydrate Metabolism
Cell Differentiation / drug effects*
Cell Line
Drug Carriers / chemistry
Drug Delivery Systems*
Flow Cytometry
Glycosylation
Humans
Lactic Acid / chemistry
Macrophages / metabolism
Monocytes / metabolism
Nanoparticles
Plant Lectins / metabolism*
Polyglycolic Acid / chemistry
Temperature
Tetradecanoylphorbol Acetate / analogs & derivatives,  pharmacology
Wheat Germ Agglutinins / metabolism*
Chemical
Reg. No./Substance:
0/Drug Carriers; 0/Plant Lectins; 0/Wheat Germ Agglutinins; 0/polylactic acid-polyglycolic acid copolymer; 16561-29-8/Tetradecanoylphorbol Acetate; 26009-03-0/Polyglycolic Acid; 50-21-5/Lactic Acid; 56937-68-9/phorbolol myristate acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Magnetic resonance imaging of tablet dissolution.
Next Document:  Oral osmotically driven systems: 30 years of development and clinical use.